

This listing of claims will replace all prior versions and listings of claims in the application:


Listing of Claims:

Cancel claims 1-10 without prejudice or disclaimer.

11. (currently amended) A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt according to claim 13 and a pharmaceutically acceptable carrier.

12. (canceled) A method of treating a mammal in need thereof for a disorder of neuropeptide Y activity comprising administering to said mammal an effective amount of a compound or a pharmaceutically acceptable salt according to claim 13.

13. (previously presented) A compound of the formula



wherein:

W_2 is not present or is selected from the group consisting of C=O, SO₂, SO, and C(O)NH;

A^1 is selected from the group consisting of O, S, NH, N-lower alkyl, and N-aryl;

R^1 and R^3 are each independently selected from the group consisting of: H; and cyclic or acyclic straight- or branched-chain, saturated or unsaturated C₁-C₁₄ alkyl groups, which are unsubstituted or substituted with one or more substituents selected from the group consisting of hydroxy, lower alkoxy, alkylthio, aryloxy, and arylthio groups, where the aryl-bearing groups are each unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, lower alkoxy, alkylthio, lower alkyl, trifluoromethoxy, trifluoroethoxy, and trifluoromethyl groups, and the alkyl-bearing groups are unsubstituted or substituted with one or more substituents selected from the group consisting of cyclic structures having a ring size of from 3 to 10 atoms and aryl and heteroaryl groups unsubstituted or substituted with one or more

substituents selected from the group consisting of lower alkyl, alkoxy, amino, lower alkylamino, lower acylamino, halogen, trifluoromethyl and trifluoromethoxy groups;

R5, R7, R9, and R11 (where present) are each independently selected from the group consisting of: H; cyclic or acyclic straight- or branched-chain, saturated or unsaturated C1-C14 alkyl groups, which are unsubstituted or substituted with one or more substituents selected from the group consisting of non-aromatic cyclic structures having from 3 to 14 ring atoms, aromatic and heteroaromatic structures, and heterocyclic rings having from 4 to 12 ring atoms, the aromatic and heteroaromatic structures being unsubstituted or substituted with one or more substituents selected from the group consisting of lower alkyl, alkoxy, amino, lower alkylamino, lower acylamido, halogen, perfluoroalkyl, perfluoro-lower alkoxy, and aryl and heteroaryl groups, the aryl and heteroaryl groups being unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, lower alkoxy, alkylthio, lower alkyl, trifluoromethoxy and trifluoromethyl groups; and aryl and heteroaryl groups unsubstituted or substituted with one more substituents selected from the group consisting of halogen, lower alkoxy, alkylthio, lower alkyl, trifluoromethoxy, and trifluoromethyl groups;

R6 is selected from the group consisting of H, R6', R6'-NH, and R6'-N-lower alkyl, where R6' is selected from the group consisting of: cyclic or acyclic straight- or branched-chain, saturated or unsaturated C1-C14 alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; condensed aryl-lower alkyl; condensed heteroaryl-lower alkyl; bis-aryl-lower alkyl; bis-heteroaryl-lower alkyl; heteroaryl-lower alkyl-aryl; and partially or fully saturated derivatives thereof;

R10 is selected from the group consisting of: H; and cyclic or acyclic straight- or branched-chain, saturated or unsaturated C1-C12 alkyl groups; aryl groups unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, alkoxy, aminoalkyl, di-(lower alkyl)-amino-lower alkyl, and hydroxy; arylalkyl; aryloxyalkyl; 2-tetrahydrofuryl; 3-tetrahydrofuryl; terminal hydroxyalkyl; and amidoalkyl;

or R9 and R10 together with the nitrogen to which they are bonded form a 3- to 10-membered ring;


Q is selected from: $(-CH_2)_z$, where z is an integer of from 1 to 12, unsubstituted or substituted with one or more substituents selected from the group consisting of lower alkyl, aryl, and heteroaryl, and where when z is >1 , one or more $-CH_2-$ each is optionally replaced by an atom selected from O, S, and N, with N being optionally substituted with lower alkyl, aryl, or heteroarylalkyl; $-(CH_2)_m-$ $(CH_2)_x$ $-(CH_2)_l-$, where l and m are each independently an integer of from 0 to 5 and x is an integer from 3 to 12, where $-(CH_2)_x-$ is a 3- to 12-membered saturated carbocyclic or heterocyclic ring unsubstituted or substituted with one or more substituents selected from the group consisting of lower alkyl, cycloalkyl, aryl, and heteroaryl, where when the ring is heterocyclic, one or more of the ring $-CH_2-$ units is replaced by a heteroatom selected from O, S, Se, and N, with N being unsubstituted or substituted with lower

alkyl, aryl, or heteroaryl; and $-(CH_2)_m-$ $(-CH=CH-)_y$ $-(CH_2)_l-$, where l and m are each independently an integer of from 0 to 5 and y is 2 or 3, and where $-(CH=CH-)_y-$ is a 4- to 6-membered aromatic carbocyclic or heterocyclic ring unsubstituted or substituted with one or more substituents selected from the group consisting of saturated or unsaturated, straight- or branched-chain alkyl groups, lower alkoxy groups, and halogens, where when the ring is heterocyclic, one or more of the ring $-CH-$ or $-CH=CH-$ units is replaced by a heteroatom selected from O, S, Se, and N, with N being optionally substituted with lower alkyl, aryl, or heteroaryl; and

X3 is selected from the group consisting of H, lower alkyl, aryl, lower alkoxy, hydroxy, and trifluoromethyl;


or a pharmaceutically acceptable salt thereof.

- 14.** (previously presented) A compound according to claim 13 of formula:




wherein the variables are as previously defined,
or a pharmaceutically acceptable salt thereof.

15. (previously presented) A compound or a pharmaceutically acceptable salt thereof according to claim 14, wherein Q is selected from the group consisting of:




wherein l and m are each independently 0 or 1.

16. (previously presented) A compound or a pharmaceutically acceptable salt thereof according to claim 13, wherein Q is selected from the group consisting of:




17. (previously presented) A compound or a pharmaceutically acceptable salt thereof according to claim 13, wherein the compound is of the formula:




wherein the variables are as previously defined.

18. (previously presented) A compound or a pharmaceutically acceptable salt thereof according to claim 13, wherein R6 is selected from the group consisting of aryl, heteroaryl, aryl-lower alkyl, heteroaryl-lower alkyl, condensed aryl-lower alkyl, condensed heteroaryl-lower alkyl, bis-aryl-lower alkyl, bis-heteroaryl-lower alkyl, heteroaryl-lower alkyl-aryl, and partially or fully saturated derivatives thereof.


19. (previously presented) A compound or a pharmaceutically acceptable salt thereof according to claim 13, wherein R6 is selected from the group consisting of:







20. (previously presented) A compound or a pharmaceutically acceptable salt thereof according to claim 13, wherein R10 is selected from the group consisting of: cyclic or acyclic straight- or branched-chain, saturated or unsaturated C1-C12 alkyl; aryl unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, alkoxy, aminoalkyl, di-(lower alkyl)-amino-lower alkyl, and hydroxy groups; arylalkyl; aryloxyalkyl; 2-tetrahydrofuryl; 3-tetrahydrofuryl; terminal hydroxyalkyl; and amidoalkyl.

21. (previously presented) A compound or a pharmaceutically acceptable salt thereof according to claim 13, wherein R10 is selected from the group consisting of:






22. (previously presented) A compound according to claim 13 of the formula:



wherein the variables are as previously defined,
or a pharmaceutically acceptable salt thereof.

or a pharmaceutically acceptable salt thereof.

23. (previously presented) A compound or pharmaceutically acceptable salt according to claim 22, wherein R1, R3, R5, R7, and R10 are each H.
24. (previously presented) A compound or a pharmaceutically acceptable salt thereof according to claim 14, wherein R1, R3, R5, R7, and R9 are each H; R11 (where present) is H or methyl; and A1 is NH.
25. (previously presented) A compound according to claim 13 having the formula:



or a pharmaceutically acceptable salt thereof.